First Week of KVUE August 21st Options Trading

Kenvue (KVUE) is being profiled for options income strategies around the current stock price of $17.30. Selling the $13.00 put (bid $0.06) nets an effective cost basis of $12.94 and is described as ~25% OTM with an 85% chance to expire worthless, implying a 0.46% return (0.73% annualized) if it does. A covered-call using the $18.00 strike (bid $0.91) against shares bought at $17.30 would produce a 9.31% total return to the August 21 expiration if called, the strike being ~4% OTM with a 47% chance to expire worthless and a 5.26% yield boost (8.31% annualized). Implied volatilities are ~40% (put) and 47% (call) versus a 12-month realized volatility of 35%.

Analysis

Market structure: The present option prices favor premium sellers — cash‑secured put and covered‑call writers — because the $13 put (25% OTM) yields only $0.06 with an 85% modeled chance to expire worthless while the $18 call (4% OTM) pays $0.91 with ~47% chance to expire worthless. That asymmetry (call IV 47% vs put IV 40% vs realized 35%) implies skewed demand for upside/short‑dated calls and an incumbent supply of downside protection; retail and yield‑seeking strategies win, while long‑only momentum holders risk capped upside if covered calls proliferate.

Risk assessment: Tail risks are event‑driven (product recall, regulatory action, lock‑up/earnings shock) that could produce >25% gaps and invalidate the put’s low premium; liquidity in the options chain is another operational risk. Near term (days–weeks) the August 21 expiry concentrates gamma/flow risk; medium term (months) realized volatility could reprice IV toward 50% if a shock occurs; long term fundamentals (market share in consumer health, margin trends) will determine directional drift.

Trade implications: For income‑oriented allocation, prefer cash‑secured $13 puts (target 1–3% portfolio exposure) or buy shares and sell Aug21 $18 calls (covered call) to cap upside for a ~9% to Aug21 return objective; avoid naked short positions and scale position size to liquidity (start 1% and add to 2–3% if IV contracts). If bearish, use defined‑risk put spreads or collars (buy Aug21 $15 put / sell $13 put) to limit cost while targeting >15% downside.

Contrarian angles: Consensus underestimates idiosyncratic tail risk — the low $0.06 premium can be wiped out by a single adverse event; implied vols already price a modest premium vs realized so selling is slightly favorable but fragile. Historical spin‑offs and consumer‑health shocks have produced 20–40% moves within 3–12 months; heavy short‑put concentration could amplify downside via assignment and forced buying/hedging distortions.

Key Decisions for Investors

• Sell cash‑secured KVUE Aug21 $13 put (sell‑to‑open) size = 1% portfolio notional (scale to 2–3% if liquidity allows); collect $0.06, effective basis $12.94; close/roll if KVUE < $11 (≈20% gap) or if implied probability of expiring worthless falls below 70%.
• Buy 100 KVUE shares and sell Aug21 $18 call (covered call buy‑write) to target ~9.3% return to Aug21; position limit 1–3% portfolio; if unwilling to be called, buy an Aug21 $15 protective put (collar) if protection cost <1.5% of position value.
• If bearish, buy a defined‑risk Aug21 bear put spread (e.g., buy $16 put / sell $13 put) sized to 0.5–1% portfolio to express >15% downside view while capping max loss; avoid naked short options.
• Do not initiate naked short KVUE options or outright stock shorts; monitor IVs and the contract's modeled odds daily and unwind option‑seller exposure if IV rises >+50% (from current ~40–47% to >60%) or if put expiring‑worthless probability falls under 70%.